Anais Badia, DO
Dermatology · Fort Myers, FLNPI 1609051887
Payments from drug & device makers
Across 313 payments — averaging $2436.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$239K
- Boehringer Ingelheim$211K
- Sanofi US Services Inc.$90K
- Incyte Corporation$51K
- Pfizer$48K
- Astrazeneca UK Limited$29K
- plus $94K from 33 others
Across 100 payments — averaging $798.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$51K
- Glenmark Pharmaceuticals Inc., USA$28K
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $238,885 |
| Boehringer Ingelheim | 14 | $211,194 |
| Sanofi US Services Inc. | 37 | $90,397 |
| Incyte Corporation | 29 | $51,402 |
| Pfizer | 28 | $47,693 |
| Astrazeneca UK Limited | 6 | $29,476 |
| UCB SA | 13 | $26,539 |
| UCB Biosciences Inc. | 2 | $19,124 |
| Genentech, Inc. | 4 | $17,913 |
| Dermira, Inc. | 3 | $10,400 |
| Boehringer Ingelheim Canada Ltd.ltee | 33 | $6,872 |
| Hoffmann-la Roche Limited | 9 | $6,624 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $3,094 |
| AbbVie(2 entities) | 30 | $619 |
| Johnson & Johnson | 15 | $461 |
| Arcutis Biotherapeutics, Inc. | 10 | $257 |
| Regeneron Healthcare Solutions, Inc. | 4 | $208 |
| UCB, Inc. | 3 | $194 |
| Galderma Laboratories, L.p. | 5 | $191 |
| Sanofi | 7 | $166 |
| Amgen | 3 | $159 |
| Lilly USA, LLC | 6 | $157 |
| Dermavant Sciences, Inc. | 8 | $149 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Biofrontera Inc. | 3 | $60 |
| Merck | 3 | $58 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| Kerecis Limited | 1 | $57 |
| LEO Pharma Inc. | 2 | $50 |
| EPI Health, LLC | 2 | $42 |
| Novartis | 2 | $37 |
| LNHC, Inc | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $20 |
| Sebela Pharmaceuticals Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $14 |
| Organon | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $12 |
| Strata Skin Sciences, Inc. | 1 | $12 |
How this compares
$762,731 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Fort Myers
- Michael SherlingLake Worth$78.9M
- Seth FormanTampa$28.2M
- Thomas TaylorTampa$13.6M
- Frank DonHallandale Beach$7.5M
- Francisco FloresMiramar$6.7M
- Hector Wiltz JrMiami$6.4M
- Javier Alonso-LlamazaresCoral Gables$5.6M
- Eduardo WeissHollywood$5.5M
- Francisco KerdelMiami$5.1M
- Jason SluzevichJacksonville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.